-
Tytuł:
-
Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
-
Autorzy:
-
Arrigo, Mattia
Truong, Quynh A.
Szymonifka, Jackie
Rivas-Lasarte, Mercedes
Tolppanen, Heli
Sadoune, Malha
Gayat, Etienne
Cohen-Solal, Alain
Ruschitzka, Frank
Januzzi Jr, James L.
Singh, Jagmeet P.
Mebazaa, Alexandre
Januzzi, James L Jr
-
Temat:
-
HEART failure treatment
ATRIAL natriuretic peptides
CARDIAC pacing
CONVALESCENCE
HEART failure
LONGITUDINAL method
MULTIVARIATE analysis
PEPTIDE hormones
PEPTIDES
PROTEIN precursors
TIME
VENTRICULAR remodeling
TREATMENT effectiveness
PREDICTIVE tests
PROPORTIONAL hazards models
ODDS ratio
DIAGNOSIS
-
Źródło:
-
EP: Europace; Nov2017, Vol. 19 Issue 11, p1848-1854, 7p
-
Aims: Cardiac resynchronization therapy (CRT) induces reverse cardiac remodelling in heart failure (HF), but many patients receiving CRT remain non-responders. This study assessed the role of amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), mid-regional-pro-atrial natriuretic peptide (MR-proANP), and mid-regional-pro-adrenomedullin (MR-proADM) at the time of device implantation to predict favourable clinical course (CRT response and/or risk of MACE) in HF patients receiving CRT.Methods and Results: A total of 137 HF patients were prospectively included. Blood was drawn from the coronary sinus (CS) at CRT implantation, and from a peripheral vein (PV) simultaneously and after 6 months. Clinical CRT response at 6 months and major adverse cardiovascular events (MACE) at 2 years were assessed. Baseline PV-levels of MR-proANP (202 vs. 318 pmol/L, P = 0.009) and MR-proADM (843 vs. 1112 pmol/L, P = 0.02) were lower in CRT responders compared with non-responders. At 6 months, CRT responders showed a decrease in MR-proANP levels, compared with an increase in non-responders (-32 vs. +7 pmol/L, P = 0.02). During the same period, NT-proBNP decreased by a similar way in responders and non-responders, while MR-proADM was unchanged in both groups. High baseline MR-proANP, either in PV (OR 0.41, 95% CI 0.24-0.71, P = 0.002) or CS (OR 0.32, 95% CI 0.15-0.70, P = 0.005) was associated with reduced likelihood of CRT response. Furthermore, PV and CS levels of NT-proBNP, MR-proANP, and MR-proADM were all associated with increased risk of 2-year MACE (all P < 0.01).Conclusion: Mid-regional-pro-atrial natriuretic peptide may assist prediction of clinical course in HF patients undergoing CRT implantation. Low circulating MR-proANP at the time of device implantation is associated with CRT response and more favourable outcome. [ABSTRACT FROM AUTHOR]
Copyright of EP: Europace is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)